• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172624 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  . P2 v" p5 |! A" P6 V  |" L

8 L9 {2 l& t. x* N% R+ j. C  h* [5 D/ U" F; b' \6 F) \
Sub-category:' [8 T" a# n2 E& @$ @. e+ f* r: O: N; D
Molecular Targets
* Y+ |% e% d+ I3 Z5 t* E- n% O( P6 C( k( v

  h& V! \+ P) s2 O" \9 e6 J. MCategory:/ d# L  H, m; y/ p- Y6 I% I
Tumor Biology - V, r! W* g% A2 O9 s

+ q% Z" u! m" {9 k+ n  ]2 A# c: @9 @1 K" l" ~- j0 W  T5 T6 N3 ^1 z5 A
Meeting:
. G; @* |; g% R0 w  O5 [4 n2011 ASCO Annual Meeting
1 w' ?4 C; e0 {, z) C
" c1 `; ~8 l& i: ^2 B
+ Z: h& T1 m4 d, m' wSession Type and Session Title:
6 F5 x% K1 _% K" nPoster Discussion Session, Tumor Biology
% z9 M1 p( W8 F  F3 H
0 N8 I8 o- h+ u7 W/ f8 p* y5 q2 k, B" F- q' b+ S1 A
Abstract No:9 O/ E* b3 M/ [* E4 |
10517 1 Z1 a" b# z% x4 ^/ t4 K
9 g  Z& n! e; N  \; q) g: d: X. c3 d

2 h. D, q0 C% a' V* bCitation:
4 |* s5 J  u( {2 H9 ?J Clin Oncol 29: 2011 (suppl; abstr 10517)
" H) E; w$ [6 j, e, W  A8 }9 Y$ g( C0 q0 l: E% u
, d+ E' A3 g5 u
Author(s):  B- T, L" n% m5 L5 Y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China $ ~: L; \" o% [" j! U/ `
4 T( C0 I( ^' i, o/ P

1 ?5 H; P+ P4 v0 F- P( [
# a9 t7 M2 d" q5 h* A: C+ lAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
' c7 ]$ \' C( c2 E' l$ R. K7 n) B* {+ h  K" |
Abstract Disclosures. f- T& L' q9 }" R1 c$ y: S

; C( R4 T* d; p$ f4 A; ?Abstract:1 p, [% Q' [8 \3 D$ W- Z
0 F6 q2 `% N! V( ^6 s! q

; E; T$ d. v, G$ K- y+ ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 T1 v& P  }2 o
. m0 c( I% s" A. q1 o& H / _# f; Q4 X# _7 B, i; Q' u
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
* S* P* K7 l7 O- |7 e没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

- j) w0 G: E4 q% a化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
* r2 B9 W: @% f' T9 C易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
8 Y% k5 z& D/ @+ |; yALK一个指标医院要900多 ...

, }* h/ |9 F9 n& @: M2 G7 {" R! @平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?$ ^  l0 a- I* ~) ^* r

' H) l& x' |/ x9 u. e7 [2 z现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表